New Delhi: Pfizer has introduced its latest pneumonia vaccine in India, offering protection against 20 strains of pneumococcal bacteria, known to cause acute lung infections in adults. This launch marks a significant step in strengthening adult immunisation in the country.
 

Pfizer’s new vaccine, which requires just a single dose, is designed to protect adults from a wide range of pneumococcal diseases, ranging from mild respiratory infections to life-threatening complications like bloodstream infections and meningitis. It is said to be ideal for adults over 50 and those with chronic conditions such as asthma, diabetes, kidney disease, or lung disorders, who are at higher risk of severe illness.

“We’re proud to bring this next-generation pneumonia vaccine to India,” said Meenakshi Nevatia, Managing Director of Pfizer India. She further said, “With coverage against 20 bacterial strains, this vaccine meets the immediate requirement for adult immunisation and supports our ongoing efforts to protect public health.”

Pneumonia remains a major public health challenge, particularly among older adults and people with weakened immune systems. Timely vaccination can reduce the risk of hospitalisation and death, and is strongly recommended by healthcare professionals worldwide.

With this rollout, Pfizer reaffirms its global commitment to disease prevention, extending over two decades of work in pneumonia control. Pfizer is a global biopharmaceutical company that has been at the forefront of medical breakthroughs for over 170 years. The company continues to invest in vaccines and public health initiatives that aim to protect lives and promote preventive care, long before illness begins.